From the time of inception, various chemotherapeutic agents are known to cause cardiotoxicity. The cardiotoxicity ranges from mild transient abnormality to irreversible cardiac tissue damage. Certain classes of drugs like anthracyclines are known to be cardiotoxic while some newer drugs like Transtuzumab also cause cardiotoxicity. 5 Fluorouracil is known to be cardiotoxic though the incidence is low. We present a case of cardiotoxicity due to prolonged 5 Fluorouracil infusion in a patient with adenocarcinoma of colon.
INTRODUCTION
Cardiotoxicity is a recognized chemotherapy induced adverse event. Cardiac events associated with chemotherapy vary from mild transient blood pressure and/or electrocardiographic (ECG) changes to more serious arrhythmias, myocarditis, pericarditis, myocardial infarction and cardiomyopathy, which may end in left ventricular dysfunction or congestive heart failure.
Various chemotherapy agents are known to be cardiotoxic. The drugs that predominantly cause irreversible cell destruction due to their cumulative effects, have been designated as type I agents (Table 1) , and those without cell destruction as a dominant characteristic are classifi ed as type II agents 1 . Type II agents do not exhibit toxicity that is related to cumulative dose, and their effects are reversible 2, 3 .
Though cardiotoxicity due to 5-FU is known, it is not very common. Experience of this toxicity is not reported much in this part of world. The purpose of this case report is to make clinicians familiar about this rare toxicity and to discuss about the ways to try and prevent it.
CASE REPORT
55 years old male patient presented with history of pain abdomen for 1 year duration. He was evaluated and USG abdomen revealed gall bladder stone. He underwent laparoscopic cholecystectomy however his pain persisted. He was again evaluated and contrast enhanced CT scan of abdomen was done. CT scan revealed mass lesion in the caecum. Patient was evaluated in detail, including cardiac evaluation before surgery. Clinical examination and ECG were normal. However echocardiography was not done. He was taken up for surgery and right hemicolectomy was done. Final biopsy was Ca Colon-Adenocarcinoma, TNM-pT4bN2bM0., AJCC stage IIIc, Duke stage 3.
In view of advanced stage, he was planned for adjuvant chemotherapy with FOLFOX-4 regimen ( Table 2) . He received 1st cycle of chemotherapy without any complications. After 2 days of chemotherapy, patient complained of vague discomfort along with multiple episodes of vomiting. He was managed conservatively with oral medication and recovered well. Second cycle of chemotherapy was started after 14 days according to schedule. Day 1 of chemotherapy, which included oxaliplatin followed by rapid infusion of Leucovorin & 5-FU, followed by 22 hours of 5-FU infusion, was uneventful. However on day 2, 1 hour after starting planned for 22 hours infusion of 5-FU, patient complained of dull aching persisting pain over left shoulder. Injection Tramadol was given IV and infusion was stopped. However pain persisted and he complained of vague discomfort over left precordium also. ECG was done which showed ST-T changes consistent with acute myocardial injury (Figure 1 Figure 6 ) and ECHO done after 6 weeks were normal. He is now on 3 weekly CAPOX regimen (Capecitabine + Oxaliplatin). He has completed 2 cycles and is on continued followup.
DISCUSSION

AND REVIEW OF LITERATURE
As early as 1967, there were reports of heart failure in children treated with doxorubicin 4 . Since then the cytostatic antibiotics of the anthracycline class remain the most common cardiotoxic chemotherapeutic agents.
5-FU is administered widely for varied types of malignancies like gastrointestinal, breast, and head & neck cancer. Common adverse clinical reactions such as myelosuppression, diarrhea, and mucositis have been shown to be related to the modalities of 5-FU administration like dose, schedule, or route 5 . For instance, in similar doses of 5-FU given by continuous intravenous infusion instead of bolus injection, the continuous intravenous infusion provoked less hematotoxicity but caused more mucositis and palmo-plantar dysesthesia6.
Apart from these toxicities, 5-FU is also known to cause cardiotoxicity. Gradishar and Vokes stated that highdose 5-FU therapy (> 800 mg/m 2/d) is associated with up to 10% of cardiac events 7 . Labianca reported cardiac toxicity in 1.6% of patients who were treated with 5-FU8. The study done by de Forni confi rmed signifi cant incidence (7.6%) of 5-FU cardiotoxicity following high dose continuous infusion 9 . 5-FU cardiotoxicity is more common in patients with a history of coronary artery disease 5, 10, 11 .
Although the clinical features of 5-FU cardiotoxicity are recognized widely now, the underlying physiopathology of this syndrome has not been demonstrated clearly. Various hypotheses have been proposed, which include ischemia secondary to coronary artery spasm, a direct toxicity on the myocardium, 5-FU interactions with the coagulation system, and an immune-allergic phenomena 12 . The study done by de Forni suggested that 5-FU cardiotoxicity closely resembles the stunned myocardium syndrome and might be related to a diffuse ischemia or a direct toxicity 8 .
CONCLUSION
Prophylaxis against 5-FU cardiotoxicity starts with identifying patients with underlying coronary artery disease and avoiding regimens that contain continuous 5-FU infusion in this group. Using IV bolus administration rather than continuous administration may be advisable but benefi t of continuous 5-FU infusion cannot be over emphasized. 
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